Clexio is a clinical-stage company designing novel drugs based on validated MOAs in Psychiatry and Neurology.
We are developing innovative therapies to address patients’ unmet needs in Major Depressive Disorder, Schizophrenia and Peripheral Neuropathy.
Our lead drug candidates (CLE-100 and CLE-400) are currently being tested in Phase 2 multicenter studies in the United States.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages, and regulatory approvals.
Join our vision to make lives of millions of patients worth living again.
Company Details
- Employees
- 42
- Founded
- -
- Address
- Yage Kapaim 17, Petach Tikva,israel,israel
- in****@****xio.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- clexio.com
- HQ
- Petach Tikva, Israel
Clexio Biosciences Questions
Clexio Biosciences's website is clexio.com
Clexio Biosciences's LinkedIn profile is https://il.linkedin.com/company/clexio
Clexio Biosciences has
42 employees.
View email and phone details for 42
employees at Clexio Biosciences.
Clexio Biosciences's industry is
Pharmaceutical Manufacturing
Clexio Biosciences's top competitors are
Cytoreason,
Beckley Psytech,
Teva Pharmaceuticals,
Biomx (Nyse: Phge),
Biolinerx,
Clene Nanomedicine, Inc.,
Neuroderm, A Mitsubishi Tanabe Pharma Group Company,
Neurosense Therapeutics,
Brainstorm Cell Therapeutics,
Prilenia.
Clexio Biosciences's support email address is info@clexio.com
Clexio Biosciences's categories are Pharmaceutical Manufacturing
Clexio Biosciences's founding year is 2018
